On May 28, 2021, CureVac announced that the independent Data Safety Monitoring Board (DSMB)confirmed that the pivotal Phase 2b/3 study (HERALD) for CureVacﾒs first-generation COVID-19 vaccine candidate, CVnCoV, had passed a first interim analysis at 59 adjudicated COVID-19 cases.

The DSMB confirmed that there were no safety concerns for CVnCoV.